Overall, the outlook for pharma/biotech M&A deal remains bullish for 2019 due to growing availability of capital for these firms and a lot of innovation happening in the sector.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,